We report a case of recurrent esophagogastric junction
cancer successfully treated with
chemotherapy including
trastuzumab. A 66-year-old man reporting black stool was examined, and through upper gastrointestinal endoscopy was found to have a
tumor at the esophagogastric junction. Video-assisted thoracoscopic surgery of the esophagus with 3-field
lymph node dissection was performed. The final diagnosis was adenocarcinoma(tub1-pap-muc), pT3N3M0, pStage III C. The
tumor was at the squamo-columnar junction and classified as Siewert type II . Following surgery, 6 months of adjuvant
therapy with S-1 was administered. Computed tomography(CT)confirmed
metastases in the lung, liver, and recurrence in the reconstructed stomach. In spite of
chemoradiotherapy(FP plus RT)and weekly PTX, these
metastases had grown. Pathological examinationshowed overexpressionof humanepidermal
growth factor receptor 2(HER2), and treatment with
CPT- 11 plus
trastuzumab was initiated at postoperative 15 months. A partial response was achieved 3 months later. The lesions in the lung, liver, and reconstructed stomach were controlled with this
therapy, but he died from meningeal seeding at postoperative 20 months. These findings suggest that inclusion of
trastuzumab in
chemotherapy regimens is effective for recurrent HER2-positive esophagogastric junction
cancers.